Blood Clot Prevention │Treatment
Blood Clot Prevention
Xarelto® is the first oral once-daily direct Factor Xa inhibitor (approved in the European Union for the prevention of VTE in adult patients undergoing elective hip or knee replacement surgery) with uniquely targeted action in preventing blood clots.
Blood Clot Treatment
Xarelto® precisely targets this pivotal point in the coagulation cascade, which is a chain of biochemical reactions essential to the formation of blood clots.25, 26, 27
See also: Venous Thromboembolism (VTE)
See also: Factor Xa
- 6 - Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):381S-453S.
- 25 - Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1(7):1504-1514.
- 26 - Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2007;27(6):1238-1247.
- 27 - Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis. 2008;25(1):52-60.